Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
475 Leser
Artikel bewerten:
(2)

Medacta Receives CE Marking for the Lateralized Glenosphere

EQS Group-Media / 2019-10-08 / 19:05 
 
*Press Release* 
*Medacta Receives CE Marking for the Lateralized Glenosphere* 
 
_CASTEL SAN PIETRO_, _8 October 2019_ - Medacta International has recently 
obtained CE marking for the lateralized glenosphere. This new implant 
further expands the Medacta offering for shoulder arthroplasty, which now 
features a broader range of options for reverse shoulder replacement 
surgery. 
 
The Medacta Shoulder System is a modular solution that includes wide-ranging 
sizes, adjustable offset and innovative configurations both in the anatomic 
and reverse configuration. It is compatible with, and can be further 
enhanced by, the CT-based MyShoulder 3D preoperative planning solution, 
offering patient-specific humeral and glenoid guides. 
 
The lateralized glenosphere features a more lateralized centre of rotation 
compared to the standard glenosphere already included in the Medacta 
Shoulder System offering. The potential benefits are an improved range of 
motion, as well as a reduced risk of scapular notching. 
 
This new CE mark clearance exemplifies Medacta's continuous commitment to 
leverage expertise gained throughout orthopaedics for the development of 
exceptional shoulder solutions. 
 
For more information on Medacta Shoulder System and Medacta's shoulder 
arthroplasty solutions, visit https://www.medacta.com/EN/global-shoulder 
[1]. 
 
*Contact* 
Medacta International SA 
Gianluca Olgiati 
Senior Director Global Marketing 
Phone: +41 91 696 60 60 
media@medacta.ch 
 
*About Medacta* 
Medacta is an international company specializing in the design and 
production of innovative orthopaedic products and the development of 
accompanying surgical techniques. Established in 1999 in Switzerland, 
Medacta's products and surgical techniques are characterized by innovation. 
Medacta is a pioneer in developing new offerings on the basis of minimally 
invasive surgical techniques, in particular its Anterior Minimally Invasive 
Surgery ("AMIS") technique for hip replacements. Medacta has leveraged its 
orthopaedic expertise and comprehensive understanding of the human body to 
develop the sophisticated "MySolutions" technology, which offers surgeons 
highly personalized pre-operative planning and implant placement 
methodologies by creating advanced personalized kinematic models and 3D 
planning tools for use in hip, knee, shoulder and spine procedures. 
 
Additional features: 
 
Document: http://n.eqs.com/c/fncls.ssp?u=LRTMPBMUWY [2] 
Document title: Medacta Receives CE Marking for the Lateralized Glenosphere 
 
Issuer: Medacta Group SA 
Key word(s): Advertisement/Communication 
 
End of Corporate News 
Language:    English 
Company:     Medacta Group SA 
             Strada Regina 
             6874 Castel San Pietro 
             Switzerland 
Phone:       +41 696 6060 
E-mail:      info@medacta.ch, investor.relations@medacta.ch 
Internet:    www.medacta.com 
ISIN:        CH0468525222 
Listed:      SIX Swiss Exchange 
EQS News ID: 887253 
 
End of News EQS Group Media 
 
887253 2019-10-08 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=1321e0aebb484f68b82d52d43490bca2&application_id=887253&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=17cee4e22e4e873b46ea36f503fd7bd0&application_id=887253&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

October 08, 2019 13:05 ET (17:05 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2019 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.